<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00612508</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU RES 2017</org_study_id>
    <nct_id>NCT00612508</nct_id>
  </id_info>
  <brief_title>Hormonal Contraception and Vaginal Health</brief_title>
  <official_title>The Effects of Oral vs. Intravaginal Hormonal Contraception on Vaginal Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Clinical and Translational Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to help determine if the route by which women receive hormonal
      contraception causes different changes to occur in the lining of the vagina. The
      investigators plan to compare an oral route (taking birth control pills) with a vaginal route
      (using a vaginal ring).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators intend to conduct a prospective, randomized study at Oregon Health and
      Science University. This study will be conducted over six 28-day cycles. Subjects enrolled in
      the study will undergo baseline vaginal biopsy and then be randomized to receive either
      intravaginal ethinyl estradiol and etonogestrel (NuvaRing®) or oral ethinyl estradiol and
      desogestrel (Desogen®). Repeat vaginal biopsies will be obtained after three and six months
      of exposure to either oral or intravaginal hormonal contraception. These will be analyzed to
      measure the thickness of the vaginal epithelium and to quantify the presence of Langerhans
      cell, macrophages, T-lymphocytes and dendritic cells.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thickness of the Vaginal Epithelium (in mm)With Means and Standard Deviations Reported.</measure>
    <time_frame>baseline, 84 days, 168 days</time_frame>
    <description>Histologic evalation of vaginal sections was performed to measured and record the absolute thickness of the vaginal epithelium. Baseline findings were compared to biopsies after three and six cycles of treatment. Mean values were compared using T-test for paired data for baseline and 84 days, and baseline and 168 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>over 168 days</time_frame>
    <description>Self-reported treatment-related and serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Contraceptive Usage</condition>
  <condition>Vaginal Epithelial Disruption</condition>
  <arm_group>
    <arm_group_label>Desogen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: ethinyl estradiol and desogestrel
1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol; secen inactive pills every 28 days.
Subjects receive baseline vaginal biopsy, followed by treatment with the OC for six cycles and repeat biopsy at 3 and after 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NuvaRing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravaginal Contraception
ethinyl estradiol (0.15 mg/d) and etonogestrel (0.12 mg/d) Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
Subjects had baseline vaginal biopsy followed by 6 cycles of ring use and repeat biopsy at 3 and after 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desogen (ethinyl estradiol and desogestrel)</intervention_name>
    <description>1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol</description>
    <arm_group_label>Desogen</arm_group_label>
    <other_name>Desogen®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NuvaRing (ethinyl estradiol and etonogestrel)</intervention_name>
    <description>Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring</description>
    <arm_group_label>NuvaRing</arm_group_label>
    <other_name>NuvaRing®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  18-35 years

          -  In general good health

          -  With regular menses (every 28-32 days)

          -  Seeking contraception and willing to use a hormonal method for at least 6 months

        Exclusion Criteria:

          -  Current or recent (within the past 8 weeks) vaginitis or pelvic inflammatory disease

          -  History of recurrent vaginitis (&gt; 2 episodes in one year, any type)

          -  Pregnancy

          -  Recent use of hormonal contraceptives

          -  Depot medroxyprogesterone: 6 months

          -  Progestin implants: 3 months

          -  Oral contraceptives: 3 months

          -  Hormone impregnated IUD: 3 months

          -  Contraindications to use of oral contraceptive pills or vaginal ring

          -  History of deep vein thrombosis

          -  Known coagulopathy or thrombophilia

          -  Unexplained vaginal bleeding

          -  Uncontrolled hypertension

          -  Diabetes with vascular changes

          -  Present or history of hepatic disease or liver tumors

          -  Migraines with neurologic changes

          -  Myocardial infection

          -  Pulmonary embolus

          -  Stroke

          -  Breast cancer

          -  Hypersensitivity or allergy to hormonal contraception

          -  Heavy Smoking ( ≥ 15 cigarettes per day)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey T Jensen, MD., MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <results_first_submitted>December 16, 2010</results_first_submitted>
  <results_first_submitted_qc>October 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 8, 2012</results_first_posted>
  <last_update_submitted>October 9, 2012</last_update_submitted>
  <last_update_submitted_qc>October 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jeffrey Jensen</investigator_full_name>
    <investigator_title>MD MPH</investigator_title>
  </responsible_party>
  <keyword>contraception</keyword>
  <keyword>NuvaRing</keyword>
  <keyword>Desogen</keyword>
  <keyword>vaginal biopsy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Desogen</title>
          <description>oral contraceptive</description>
        </group>
        <group group_id="P2">
          <title>NuvaRing</title>
          <description>intravaginal contraception</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4">5 desogen users returned for the 84 day biopsy</participants>
                <participants group_id="P2" count="3">6 nuvaring users returned for the 84 day biopsy</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Desogen</title>
          <description>oral contraceptive</description>
        </group>
        <group group_id="B2">
          <title>NuvaRing</title>
          <description>intravaginal contraception</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="4"/>
                    <measurement group_id="B2" value="24" spread="3.4"/>
                    <measurement group_id="B3" value="25.8" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Thickness of the Vaginal Epithelium (in mm)With Means and Standard Deviations Reported.</title>
        <description>Histologic evalation of vaginal sections was performed to measured and record the absolute thickness of the vaginal epithelium. Baseline findings were compared to biopsies after three and six cycles of treatment. Mean values were compared using T-test for paired data for baseline and 84 days, and baseline and 168 days</description>
        <time_frame>baseline, 84 days, 168 days</time_frame>
        <population>A total of 14 subjects (7 R, 7 P) were randomized and had an initial biopsy; 11 (6 R, 5 P) returned for a biopsy at 3rd cycle (84 days), and 6 (3 R, 4 P) 6th cycle (168 days).
The analysis used a paired T test comparing the baseline mean to the mean as the end of the 3rd cylce (e.g. 84 days) and the 6th cycle (168 days)</population>
        <group_list>
          <group group_id="O1">
            <title>Desogen</title>
            <description>oral contraceptive = P (pill)</description>
          </group>
          <group group_id="O2">
            <title>NuvaRing</title>
            <description>intravaginal contraception = R (ring)</description>
          </group>
        </group_list>
        <measure>
          <title>Thickness of the Vaginal Epithelium (in mm)With Means and Standard Deviations Reported.</title>
          <description>Histologic evalation of vaginal sections was performed to measured and record the absolute thickness of the vaginal epithelium. Baseline findings were compared to biopsies after three and six cycles of treatment. Mean values were compared using T-test for paired data for baseline and 84 days, and baseline and 168 days</description>
          <population>A total of 14 subjects (7 R, 7 P) were randomized and had an initial biopsy; 11 (6 R, 5 P) returned for a biopsy at 3rd cycle (84 days), and 6 (3 R, 4 P) 6th cycle (168 days).
The analysis used a paired T test comparing the baseline mean to the mean as the end of the 3rd cylce (e.g. 84 days) and the 6th cycle (168 days)</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mean difference at 84 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.06"/>
                    <measurement group_id="O2" value="-0.005" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mean difference at 168 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.09"/>
                    <measurement group_id="O2" value=".007" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Self-reported treatment-related and serious adverse events</description>
        <time_frame>over 168 days</time_frame>
        <population>All subjects that were enrolled were assessed for adverse events at each study visit. Measure is number of participants with event</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Contraceptive</title>
            <description>Desogen (ethinyl estradiol &amp; desogestrel) = P (pill)</description>
          </group>
          <group group_id="O2">
            <title>Intravaginal Ring Contraceptive</title>
            <description>nuvaring (ethinyl estradiol &amp; desogestrel) = R (ring)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Self-reported treatment-related and serious adverse events</description>
          <population>All subjects that were enrolled were assessed for adverse events at each study visit. Measure is number of participants with event</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Every 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Desogen</title>
          <description>oral contraceptive</description>
        </group>
        <group group_id="E2">
          <title>NuvaRing</title>
          <description>intravaginal contraception</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>SNOMED-CT 289530006</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding from vagina</sub_title>
                <description>Minor bleeding and pain associated with biopsy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Did not fully recruit; small number of subject</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Oregon Health &amp; Science University</name_or_title>
      <organization>Women's Health Research Unit</organization>
      <phone>503-494-3666</phone>
      <email>whru@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

